DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia

Information source: AstraZeneca
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Schizophrenia

Intervention: Quetiapine Fumarate Extended- Release (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: AstraZeneca

Official(s) and/or principal investigator(s):
Pierre Chue, MD, Principal Investigator, Affiliation: University of Alberta
Willie Early, MD, Study Chair, Affiliation: AstraZeneca


A Multicentre, Open-label, Prospective Long-term Study Evaluating the Clinical Benefit and Effectiveness of SEROQUEL XR (Quetiapine Fumarate Extended-Release Tablets) in Subjects with Schizophrenia.

Clinical Details

Official title: A Multicentre, Open-label, Prospective Long-term Study Evaluating the Clinical Benefit and Effectiveness of SEROQUEL XR (Quetiapine Fumarate Extended-Release Tablets) in Subjects With Schizophrenia

Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study

Secondary outcome:

Change in Clinical Global Impression-Clinical Benefit (CGI-CB) Score

Change in Positive and Negative Syndrome Scale for Schizophrenia (PANSS) Total Score

Change in Positive and Negative Syndrome Scale for Schizophrenia (PANSS) Positive Scale Score

Change in Positive and Negative Syndrome Scale for Schizophrenia (PANSS) Negative Scale Score

Change in Global Assessment Scale (GAS)

Change in Clinical Global Impression-Severity (CGI-S) Scale

Change in Clinical Global Impression-Improvement (CGI-I) Scale

Change in Social and Occupational Functioning Assessment Scale (SOFAS)

Change in Safety Measure: Simpson-Angus Scale (SAS)

Change in Barnes Akathisia Rating Scale (BARS)


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria:

- Provision of written informed consent before initiation of any study related


- Male and female subjects aged 18 to 65 years, inclusive.

- Documented clinical diagnosis meeting the Diagnostic and Statistical Manual of Mental

Disorders, 4th edition (DSM-IV) criteria for any of the following: Schizophrenia DSM-IV, catatonic 295. 20, disorganised 295. 10, paranoid 295. 30 and undifferentiated 295. 90.

- Outpatient status.

- Subjects who in their own and/or in the Principal Investigator's opinion, consider

their ongoing antipsychotic treatment inadequate because of insufficient efficacy, poor tolerance, and/or non acceptability of their actual dosage regimen (eg. b. i.d, t. i.d, etc).

- Monotherapy with current antipsychotic for at least 7 days prior to initiating

treatment (ie, cannot be on more than one antipsychotic during the 7 day period prior to initiating study medication). Note: Subjects on a b. i.d regimen of seroquel IR for 7 days prior to enrolment are eligible to participate in the study.

- Female subjects of childbearing potential must have a negative serum pregnancy test

at enrolment and be willing to use a reliable method of birth control, ie, barrier method, oral contraceptive, implant, dermal contraception, long-term injectable contraceptive, intrauterine device, or tubal ligation during the study.

- Capable to make treatment decisions, including being able to understand and comply

with the requirements of the study, and judged as such by the Principal Investigator.

- Be able to read and write either English or French at a grade 7 proficiency level.

Exclusion Criteria:

- First episode, drug naive schizophrenic subjects.

- Meeting the criteria for any other (than schizophrenia) DSM-IV Axis I diagnosis,

concomitant organic mental disorder or mental retardation that in the opinion of the Principal Investigator may interfere with study conduct or interpretation.

- Substance/alcohol dependence or abuse at enrolment [except dependence in full

remission (>3 months) and except caffeine and nicotine dependence] as defined by DSM-IV criteria. A urine drug screen will be performed. The Principal Investigator will evaluate the results along with medical history to determine if the patient meets DSM-IV criteria for substance abuse or dependence. However, a single urine toxicology screen for cocaine, heroin, methamphetamine or PCP will lead to exclusion.

- Subjects requiring treatment with another antipsychotic agent than investigational

product during study.

- Subjects on seroquel IR once daily.

- Known lack of response to clozapine or treatment with clozapine within 4 weeks prior

to enrolment.

- Known intolerance to seroquel IR.

- Subjects requiring treatment with disallowed medication following enrolment into the


- Subjects requiring treatment for epilepsy.

- Subjects who pose an imminent risk of suicide or danger to themselves or others, as

judged by the Principal Investigator.

- Pregnancy or lactation.

- A thyroid-stimulating hormone (TSH) concentration more than 10% above the upper limit

of the normal range of the laboratory used for sample analysis whether or not the patient is being treated for hypothyroidism or hyperthyroidism.

- Use of a depot or long-acting injectable antipsychotic drug within 1 dosing interval

before Day 1 of treatment or during treatment.

- Use of drugs that induce or inhibit the hepatic metabolising cytochrome P450 3A4

enzymes within 14 days of the screening assessment period (Day - 7 to 0). See Table 5.

- History of idiopathic or drug-induced agranulocytosis.

- A QTc interval longer than 450 msec (calculated using the Fridericia correction for

heart rate) or ECG considered to show cardiac abnormality at enrolment as determined by a centrally located, experienced cardiologist, and confirmed by the Principal Investigator as clinically significant.

- Evidence of clinically relevant disease (eg, renal, hepatic, autonomic, endocrine,

hematologic or ophthalmologic impairment, significant coronary artery disease, congestive heart failure, cerebrovascular disease, viral hepatitis B or C, acquired immunodeficiency syndrome [AIDS] or cancer) or a clinical finding that is unstable or that, in the opinion of the Principal Investigator, would be negatively affected by the investigational product or that would affect the investigational product.

- Laboratory test results outside the reference range considered by the Principal

Investigator to be clinically significant and potentially interfere with the study outcome.

- A patient with Diabetes Mellitus (DM) fulfilling one of the following criteria:

- Unstable DM defined as HbA1c >8. 5% at enrolment. Admitted to hospital for

treatment of DM or DM related illness in past 12 weeks.

- Not under care of physician responsible for patient's DM care.

- Physician responsible for patient's DM care has not indicated that patient's DM

is controlled.

- Physician responsible for patient's DM care has not approved patient's

participation in the study.

- Has not been on the same dose of oral hypoglycemic drug(s) and/or diet for the

four (4) weeks prior to randomisation. For thiazolidinediones (glitazones) this period should not be less than 8 weeks.

- Taking insulin whose daily dose on one occasion in the past 4 weeks has been

more than 10% above or below their mean dose in the preceding 4 weeks. Note: If a diabetic patient meets one of these criteria the patient is to be excluded even if the treating physician believes the patient is stable and can participate in the study.

- An absolute neutrophil count (ANC) of <1. 5 x 109/L

- Inability to accommodate the visit schedule.

- History of non-compliance as judged by the Principal Investigator.

- Previous enrolment in the present study.

- Participation in another clinical study or compassionate use programme within 4 weeks

of screening (Day - 7 to 0).

- Involvement in the planning and conduct of the study (applies to both AstraZeneca

staff or staff at the study site).

Locations and Contacts

Research Site, Quebec, Canada

Research Site, HK, Hong Kong

Research Site, Calgary, Alberta, Canada

Research Site, Claresholm, Alberta, Canada

Research Site, Red Deer, Alberta, Canada

Research Site, Garran, Australian Capital Territory, Australia

Research Site, Vancouver, British Columbia, Canada

Research Site, Victoria, British Columbia, Canada

Research Site, Seoul, Korea, Korea, Republic of

Research Site, Miramichi, New Brunswick, Canada

Research Site, Newcastle, New South Wales, Australia

Research Site, St John's, Newfoundland and Labrador, Canada

Research Site, St. John's, Newfoundland and Labrador, Canada

Research Site, Sydney, Nova Scotia, Canada

Research Site, Belleville, Ontario, Canada

Research Site, Brantford, Ontario, Canada

Research Site, Chatham, Ontario, Canada

Research Site, Cornwall, Ontario, Canada

Research Site, London, Ontario, Canada

Research Site, Markham, Ontario, Canada

Research Site, Mississauga, Ontario, Canada

Research Site, Newmarket, Ontario, Canada

Research Site, Oakville, Ontario, Canada

Research Site, Orleans, Ontario, Canada

Research Site, Sudbury, Ontario, Canada

Research Site, Toronto, Ontario, Canada

Research Site, Windsor, Ontario, Canada

Research Site, Gatineau, Quebec, Canada

Research Site, Greenfield Park, Quebec, Canada

Research Site, Montreal, Quebec, Canada

Research Site, Rouyn-noranda, Quebec, Canada

Research Site, Verdun, Quebec, Canada

Research Site, Brisbane, Queensland, Australia

Research Site, Meadowbrook, Queensland, Australia

Research Site, Prince Albert, Saskatchewan, Canada

Research Site, Saskatoon, Saskatchewan, Canada

Research Site, Dandenong, Victoria, Australia

Additional Information

Starting date: March 2008
Last updated: June 22, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017